ChiCTR2500109070 版本V1.0 版本创建时间2025/09/11 09:54:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500109070 

最近更新日期:

Date of Last Refreshed on:

2025-09-11 09:54:36 

注册时间:

Date of Registration:

2025-09-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

上海临床队列-系统性红斑狼疮(储备)

Public title:

Shanghai Clinical Cohort – Systemic Lupus Erythematosus (Reserve)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

上海临床队列-系统性红斑狼疮(储备)

Scientific title:

Shanghai Clinical Cohort – Systemic Lupus Erythematosus (Reserve)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

丁慧华 

研究负责人:

沈南 

Applicant:

Ding Huihua 

Study leader:

Shen Nan 

申请注册联系人电话:

Applicant telephone:

+86 21 5388 2280

研究负责人电话:

Study leader's
telephone:

+86 21 5388 2280

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dinghuihua@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

nanshensibs@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区山东中路145号

研究负责人通讯地址:

上海市黄浦区山东中路145号

Applicant address:

145 Shandong Middle Road, Huangpu District, Shanghai, China

Study leader's address:

145 Shandong Middle Road, Huangpu District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属仁济医院

Applicant's institution:

Shanghai Jiao Tong University School of Medicine,Renji Hospital

研究负责人所在单位:

上海交通大学医学院附属仁济医院

Affiliation of the Leader:

Shanghai Jiao Tong University School of Medicine,Renji Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LY2025-240-C

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属仁济医院伦理委员会

Name of the ethic committee:

Shanghai Jiaotong University School of Medicine, Renjl Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-28 00:00:00

伦理委员会联系人:

陆麟

Contact Name of the ethic committee:

Lu Lin

伦理委员会联系地址:

上海市浦东新区浦建路160号

Contact Address of the ethic committee:

160 Pujian Road, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 6838 3364

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属仁济医院

Primary sponsor:

Shanghai Jiaotong University School of Medicine, Renjl Hospital

研究实施负责(组长)单位地址:

上海市浦东新区浦建路160号

Primary sponsor's address:

160 Pujian Road, Pudong New Area, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属仁济医院

具体地址:

上海市浦东新区浦建路160号

Institution
hospital:

Shanghai Jiaotong University School of Medicine, Renjl Hospital

Address:

160 Pujian Road, Pudong New Area, Shanghai

经费或物资来源:

上海申康医院发展中心

Source(s) of funding:

Shanghai Shenkang Hospital Development Center.

研究疾病:

系统性红斑狼疮  

Target disease:

Systemic lupus erythematosus

研究疾病代码:

M32

Target disease code:

M32

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究的核心目标是建立一个符合国际标准的多中心、前瞻性、动态系统性红斑狼疮卓越研究队列(LIFE-Lupus Initiative For Excellence)。通过与多个高水平临床中心合作,我们将构建一个涵盖成人与儿童患者的长期随访队列,并系统化、高质量地收集和储备临床表型、生物样本和多组学数据。此举旨在为SLE的临床与转化研究提供坚实的数据基础,其建设成果将与申康医联大数据平台对接。其次,我们将在上述队列基础上,纳入主中心活动性LN 患者形成LN队列,通过流式细胞术和血浆/尿液ELISA 检测寻找与疾病特征相关的生物标志物。  

Objectives of Study:

The overarching objective of this study is to establish a multicentre, prospective, dynamic systemic-lupus-erythematosus (SLE) cohort of international calibre—LIFE (Lupus Initiative For Excellence). By partnering with several high-level clinical centres, we will assemble a long-term follow-up cohort that spans both adult and paediatric patients, and systematically collect and curate high-quality clinical phenotypes, biospecimens, and multi-omics data. This endeavour will furnish a robust data foundation for clinical and translational research in SLE, and the resulting dataset will be integrated with the Shenkang Medical Big-Data Platform. Building on this cohort, we will further enrol patients with active lupus nephritis (LN) from the coordinating centre to constitute an LN sub-cohort. Using flow cytometry and ELISA of plasma and urine, we will identify biomarkers that correlate with disease characteristics.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

符合 ACR 1997,SLICC 2012和EULAR/ACR2019 三个版本诊断标准中的任意一个且知情同意参与研究的系统性红斑狼疮患者

Inclusion criteria

Adults or children with systemic lupus erythematosus who fulfil any one of the ACR 1997, SLICC 2012, or EULAR/ACR 2019 classification criteria and provide informed consent to participate in the study

排除标准:

不提供知情同意或所需采集核心数据的80%无法提供者

Exclusion criteria:

Individuals who decline to provide informed consent or from whom ≥80 % of the required core data elements cannot be obtained

研究实施时间:

Study execute time:

From 2025-04-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-30 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

1600

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属仁济医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Jiaotong University School of Medicine, Renjl Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

海军军医大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

Naval Medical University First Affiliated Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属儿科医院 

单位级别:

三甲 

Institution
hospital:

Children’s Hospital of Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院 

单位级别:

三甲 

Institution
hospital:

Huashan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

SLEDAI – 2000评分

指标类型:

主要指标

Outcome:

SLEDAI – 2000

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PGA评分

指标类型:

主要指标

Outcome:

PGA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

LLDAS低疾病活动度评估

指标类型:

主要指标

Outcome:

LLDAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SDI损伤评估

指标类型:

主要指标

Outcome:

SDI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以论文发表的形式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

in the form of a published paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一、病例记录表(Case Record Form, CRF),二、电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1.Case Record Form;2.Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-11 09:54:36